Routine genotyping to guide dual-antiplatelet therapy (DAPT) seems like a great idea. After all, argue Damani and Topol in a Viewpoint in JACC, the arguments are overwhelming, and the consequences of not rushing to adopt the new technique are dire. They write that loss-of-function and gain-of-function variants of CYP2c19 are extremely common, and are "the root [...]
http://cardiobrief.org/2010/05/12/topol-vs-gurbel-experts-split-on-routine-genotyping-for-dapt/
No comments:
Post a Comment